What Cortexyme Inc.’s chief operating officer Christopher Lowe called “a giant step forward” in Alzheimer’s disease (AD) research with atuzaginstat (COR-388) was viewed differently by Wall Street, which walloped shares (NASDAQ:CRTX) by 76%, or $44.17, causing the stock to close at $13.51.
Cerecin Inc. has raised $40 million in an oversubscribed round of financing, paving the way for a potential listing in South Korea. Proceeds of the financing will fund the expansion of the company’s current studies and support the planning and initiation of a global phase III study of its lead candidate, tricaprilin, in Alzheimer’s disease.
The third time proved the charm for Adamis Pharmaceuticals Corp.’s high-dose naloxone injection, Zimhi, which gained FDA approval for use in treating opioid overdose, nearly three years after the San Diego-based company first submitted an NDA.
Biogen Inc.’s phase III trial of tofersen in a form amyotrophic lateral sclerosis (ALS) has missed its main goal, but the company said it is still talking with regulators after seeing positive trends in the data.
PTC Therapeutics Inc. is already established as a player in rare diseases, working with Roche Holding AG to develop and market Evrysdi (risdiplam) to treat certain patients with spinal muscular atrophy. With Evrysdi now approved in the U.S. and Europe, and Translarna (ataluren) approved in Europe for Duchenne muscular dystrophy, South Plainfield, N.J.-based PTC is approaching a crucial juncture with its first gene therapy product.
Bumetanide, a diuretic pill commonly used for treating fluid retention for those with heart, kidney or liver disease, showed a significantly lower prevalence of Alzheimer’s disease in its users than those not taking it.
Dublin – Shares in Combigene AB, a little-known Swedish gene therapy firm, surged upward by 172% Oct. 12 on news of a preclinical licensing deal in epilepsy with Spark Therapeutics, which is potentially worth $328.5 million.
Supernus Pharmaceuticals Inc. CEO Jack Khattar, in disclosing his firm’s plan to acquire Adamas Pharmaceuticals Inc., said the team there has made “significant progress in redirecting” the Parkinson’s disease (PD) drug Gocovri (amantadine), but plenty more potential remains on the table with the oral selective RET kinase inhibitor.
Pacira Biosciences Inc. will add to its core non-opioid-based therapies business by buying Flexion Therapeutics Inc. for $427 million. That brings into the company’s fold Zilretta (triamcinolone acetonide extended-release injectable suspension) for treating osteoarthritis knee pain, an injectable non-opioid that’s already FDA approved in addition to being in a phase II study for treating shoulder osteoarthritis.
RSS
